BioSpace News Archive

I-Mab today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab,

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announces the debut of positive data on September 18, 2022.

AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that chairman and CEO Hans Keirstead, Ph.D., will deliver a keynote address at AI for Good, a program dedicated to achieving the United Nations Sustainable Development Goals through practical AI applications.

Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Lee Health has acquired the Anovo™ Surgical System, the first and only FDA-authorized surgical robot with features designed to mimic human arms and provide human level dexterity.

Turn Biotechnologies today announced it has created a novel platform to safely and effectively deliver nucleic acid therapeutics – a major expansion of the company’s business.

WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators.

RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [ 18 F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced a letter to shareholders.

ValGenesis, Inc. and Xevalics Consulting have partnered to deliver best-in-class digital validation solutions for the life sciences industry across the U.S.